Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,245 across all filing types
Latest filing 2021-01-25 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Interim / Quarterly Report Classification · 95% confidence The document is titled as an extract of unaudited financial results for the quarter and nine months ended December 31, 2020. It references Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs quarterly financial results disclosures. The document contains detailed financial data including revenue, profit, earnings per share, and other financial metrics for the quarter and nine months ended December 31, 2020, as well as comparative periods. It is not a full annual report but a periodic financial disclosure for a period shorter than a full fiscal year. The document is not merely an announcement or a certification but contains substantive financial data and analysis. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2021
2021-01-25 English
Pursuant to the provisions of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the extract copies ....
Regulatory Filings
2021-01-25 English
Updates
Regulatory Filings Classification · 90% confidence The document text is extremely short (355 characters) and consists only of an address and stock exchange listing information without any substantive content, financial data, or report details. It does not contain any financial statements, management discussion, or regulatory content. It appears to be a brief notice or header related to stock exchange listing but lacks any report or announcement content. Given the brevity and lack of detail, this fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous filings that do not fit other specific categories.
2021-01-22 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is extremely short (355 characters) and consists only of an address to stock exchange listing departments with no substantive content or financial data. There is no indication of a report, announcement, or detailed information. It appears to be a brief communication or cover letter without any report attached or described. According to the rules, such short, non-substantive documents that do not fit other categories should be classified as Regulatory Filings (RNS).
2021-01-22 English
This is with reference to the Board Meeting of the Company which was held yesterday i.e. Thursday, January 21, 2021, the Board has considered and approved the 'Commencement of construction ....
Regulatory Filings Classification · 95% confidence The document is an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about the Board Meeting decision to commence construction of a new manufacturing unit and the extension of the closure of the trading window for insiders. The document is a regulatory announcement related to compliance and insider trading restrictions, not a financial report, earnings release, or management discussion. It is short (3168 characters) and serves as a formal notification to the stock exchange and shareholders. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-01-22 English
This is with reference to the Board Meeting of the Company which was held yesterday i.e. Thursday, January 21, 2021, the Board has considered and approved the 'Commencement of construction ....
Regulatory Filings Classification · 95% confidence The document is an intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about the Board Meeting held on January 21, 2021, where the Board approved the commencement of construction of a new manufacturing unit. It also announces the continuation of the closure of the trading window for insiders until February 1, 2021. The document is a regulatory announcement related to compliance and insider trading regulations, not a financial report, earnings release, or management discussion. It is relatively short (3168 characters) and serves as a formal notification to the stock exchange and public. Therefore, it fits best under Regulatory Filings (RNS).
2021-01-22 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.